Zhejiang Guobang Pharmaceuticals, China, 2025

GMP Audit Report

Company
Zheijiang Guobang Pharmaceuticals

Product(s)
Diclazuril, enrofloxacine, marbofloxacine, danofloxacin, gamithromcin, tulatromycin

Country
China

Audit Year
2025